Other OTC - Delayed Quote USD

Agile Therapeutics, Inc. (AGRX)

0.3995 +0.0200 (+5.27%)
At close: 3:40 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
19,593.0000
19,593.0000
10,884.0000
4,101.0000
749.0000
Cost of Revenue
8,978.0000
8,978.0000
6,836.0000
10,718.0000
282.0000
Gross Profit
10,615.0000
10,615.0000
4,048.0000
-6,617.0000
467.0000
Operating Expense
30,499.0000
30,499.0000
45,482.0000
64,388.0000
49,520.0000
Operating Income
-19,884.0000
-19,884.0000
-41,434.0000
-71,005.0000
-49,053.0000
Net Non Operating Interest Income Expense
-1,341.0000
-1,341.0000
-3,051.0000
-3,889.0000
-2,800.0000
Other Income Expense
6,760.0000
6,760.0000
14,398.0000
3,827.0000
--
Pretax Income
-14,465.0000
-14,465.0000
-30,087.0000
-71,067.0000
-51,853.0000
Tax Provision
--
--
-4,675.0000
--
--
Net Income Common Stockholders
-14,465.0000
-14,465.0000
-25,412.0000
-71,067.0000
-51,853.0000
Diluted NI Available to Com Stockholders
-14,465.0000
-14,465.0000
-25,412.0000
-71,067.0000
-51,853.0000
Basic EPS
-6.71
--
-58.79
-1.46k
-1.22k
Diluted EPS
-6.71
--
-58.79
-1.46k
-1.22k
Basic Average Shares
2,156.7260
--
432.2190
48.5360
42.3410
Diluted Average Shares
2,156.7260
--
432.2190
48.5360
42.3410
Total Operating Income as Reported
-19,884.0000
-19,884.0000
-52,556.0000
-71,005.0000
-49,053.0000
Total Expenses
39,477.0000
39,477.0000
52,318.0000
75,106.0000
49,802.0000
Net Income from Continuing & Discontinued Operation
-14,465.0000
-14,465.0000
-25,412.0000
-71,067.0000
-51,853.0000
Normalized Income
-21,225.0000
-21,225.0000
-37,578.3100
-74,894.0000
-51,853.0000
Interest Income
78.0000
78.0000
80.0000
25.0000
309.0000
Interest Expense
1,419.0000
1,419.0000
3,131.0000
3,914.0000
3,109.0000
Net Interest Income
-1,341.0000
-1,341.0000
-3,051.0000
-3,889.0000
-2,800.0000
EBIT
-13,046.0000
-13,046.0000
-26,956.0000
-67,153.0000
-48,744.0000
EBITDA
-12,660.0000
-12,660.0000
-25,422.0000
-64,930.0000
-48,468.0000
Reconciled Cost of Revenue
8,978.0000
8,978.0000
6,836.0000
10,718.0000
282.0000
Reconciled Depreciation
386.0000
386.0000
1,534.0000
2,223.0000
276.0000
Net Income from Continuing Operation Net Minority Interest
-14,465.0000
-14,465.0000
-25,412.0000
-71,067.0000
-51,853.0000
Total Unusual Items Excluding Goodwill
6,760.0000
6,760.0000
14,398.0000
3,827.0000
--
Total Unusual Items
6,760.0000
6,760.0000
14,398.0000
3,827.0000
--
Normalized EBITDA
-19,420.0000
-19,420.0000
-39,820.0000
-68,757.0000
-48,468.0000
Tax Rate for Calcs
--
--
0.0002
--
--
Tax Effect of Unusual Items
--
--
2,231.6900
--
--
12/31/2020 - 5/23/2014

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

EGRX Eagle Pharmaceuticals, Inc.
4.7500
+3.04%
 
DRRX DURECT Corporation
0.9438
-1.69%
 
AYTU Aytu BioPharma, Inc.
2.9600
-3.27%
 
TLLTF TILT Holdings Inc.
0.0345
+11.29%
 
ETON Eton Pharmaceuticals, Inc.
3.6500
0.00%
 
HROW Harrow, Inc.
16.16
+1.48%
 
SHWZ Medicine Man Technologies, Inc.
0.5200
+1.96%
 
CYTH Cyclo Therapeutics, Inc.
1.3700
-4.20%
 
SBFM Sunshine Biopharma, Inc.
0.8900
-0.27%
 
BFRI Biofrontera Inc.
1.0900
-9.92%